SN50 |
Katalog-Nr.GC31642
One-Click Copy Product Info
|
SN50 ist ein zellgängiges NF-κB-Inhibitor-Peptid.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 213546-53-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SN50 ist ein zellgängiges NF-κB-Inhibitor-Peptid. Es besteht aus der hydrophilen Region des Signalpeptids des Kaposi-Fibroblasten-Wachstumsfaktors als Membrantranslozierungsmotiv und einer Kernlokalisierungssequenz der p50-Untereinheit von NF-κB[1].
SN50(20 µg/ml; 12 Stunden) induziert die Differenzierung von Mikroglia zum M2-Typ über den NF-κB-Signalweg. Die durch SN50 induzierten Mikroglia schützen Neuronen vor hypoxischen Schäden[2]. SN50(25 µg/ml; 24 Stunden) induziert eine starke Differenzierung von GSC. Die differenzierten Tochterzellen verlieren die neuroglobuläre Motilität, Invasivität und die für Tumorstammzellen typische Unempfindlichkeit gegenüber Behandlungen[4].
SN50(100 µl, 10, 30, 60 µg/ml; i.p.; 1 Stunde) milderte die alveoläre Hyperkoagulation und die Fibrinolyse-Hemmung bei ARDS durch Hemmung der NF-κB p65-Translokation[5]. SN50(1µM) schützte isolierte Rattenlungen vor LPS-induzierter Lungenschädigung durch Hemmung der nukleären NF-κB-Translokation[6]. Topisch angewendetes SN50 (10 µM; 12 Tage) unterdrückte die Aktivierung des nukleären Faktors κB in lokalen Zellen und reduzierte die Häufigkeit von Epitheldefekten/Ulzerationen in heilenden Hornhäuten von C57BL/6-Mäusen[7].
References:
[1]. Lin YZ, Yao SY,et al. Inhibition of nuclear translocation of transcription factor NF kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270(24):14255-8.
[2]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[3]. Zhang L, Ren X, et,al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May;15(5):602-11. doi: 10.4161/cbt.28158. Epub 2014 Feb 20. PMID: 24557012; PMCID: PMC4026083.
[4]. Zhao K, Zhu BS, et,al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013 Dec 30;9(6):990-8. doi: 10.5114/aoms.2013.39790. Epub 2013 Dec 26. PMID: 24482641; PMCID: PMC3902720.
[5]. Wu Y, Wang Y, et,al.SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation. Respir Res. 2020 May 27;21(1):130. doi: 10.1186/s12931-020-01372-6. PMID: 32460750; PMCID: PMC7251840.
[6]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[7]. Saika S, Miyamoto T, et,al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005 May;166(5):1393-403. doi: 10.1016/s0002-9440(10)62357-7. PMID: 15855640; PMCID: PMC1606394.
| Zellexperiment [1]: | |
Zelllinien | Gliom-Stammzellen GSC11 und GSC23 |
Vorbereitungsmethode | Die Zellen wurden 24 Stunden lang in einem Medium kultiviert, das 2% B-27, 20 ng/mL EGF und 20 ng/mL β-FGF enthielt, in Gegenwart oder Abwesenheit von SN50 (25 µg/mL). |
Reaktionsbedingungen | 25 µg/ml; 24 Stunden |
Anwendungen | SN50 kann die Differenzierung von GSC induzieren. |
| Tierversuch [2]: | |
Tiermodelle | Männliche Balb/c-Mäuse(8-12 Wochen) |
Vorbereitungsmethode | Mäuse wurden durch Inhalation von 50 µl Lipopolysaccharid(LPS) (4 mg/ml) behandelt. Eine Stunde vor der LPS-Inhalation wurde den Mäusen intraperitoneal eine unterschiedliche Dosis SN50 injiziert. |
Dosierungsform | 100 µl,10, 30, 60 µg/ml; i.p.; 1 Stunde |
Anwendungen | SN50 hemmte das Expressionsniveau von TF und PAI-1 auf mRNA- und Proteinebene in LPS-induzierten Mäusen mit akutem Atemnotsyndrom(ARDS). |
References: | |
| Cas No. | 213546-53-3 | SDF | |
| Canonical SMILES | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | ||
| Formula | C129H230N36O29S | M.Wt | 2781.5 |
| Löslichkeit | Water : ≥ 50 mg/mL (17.98 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 359.5 μL | 1.7976 mL | 3.5952 mL |
| 5 mM | 71.9 μL | 359.5 μL | 719 μL |
| 10 mM | 36 μL | 179.8 μL | 359.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)